铂-195m SPECT的临床前成像特征与定量分析
该研究评估了铂-195m(195mPt)SPECT在小鼠体内的成像可行性、图像质量与定量准确性。使用NanoSPECT/CT和U-SPECT+/CT扫描模型及健康小鼠,SPECT与伽马计数器的Spearman相关系数为0.92,与石墨炉原子吸收光谱为0.84。结论认为临床前195mPt SPECT可行,图像质量良好且信号定量准确。
要点
- 30分钟采集的模型图像对两台扫描仪均视觉可接受,NanoSPECT最小可见棒径0.95毫米,U-SPECT+为0.85毫米。
- 小鼠图像视觉可接受,可见肾、肝、血、肠摄取及膀胱排泄,脑未见摄取。
- SPECT与伽马计数器相关系数0.92,与GF-AAS为0.84,GF-AAS与伽马计数器为0.97(均P<0.0001)。
核心结论
- 临床前195mPt SPECT在可接受的示踪剂剂量和采集时间下可行,并提供良好的图像质量和准确的信号定量。
研究设计与样本
- 使用富集>96%的194Pt在高通量反应堆(HFR,荷兰Petten,NRG)辐照,获得比活度33 MBq/mg的0.05 M HCl 195mPt溶液。
- 图像质量评估使用NanoSPECT/CT(Bioscan Inc.,美国华盛顿特区)和U-SPECT+/CT(MILabs BV,荷兰乌得勒支)扫描仪。
- 填充1 MBq 195mPt、棒径0.85-1.7毫米的放射性棒模型以不同采集时间(10-120分钟)扫描。
- 四只健康小鼠静脉注射3-4 MBq 195mPt,注射后0、2、4或24小时用NanoSPECT采集120分钟图像,扫描后立即处死小鼠,以伽马计数器和石墨炉原子吸收光谱(GF-AAS)作为参考标准测定器官铂浓度。
主要发现
- 模型30分钟采集对两台扫描仪均提供视觉可接受的图像质量,NanoSPECT最小可见棒径0.95毫米,U-SPECT+为0.85毫米。
- 小鼠图像视觉可接受,肾脏见摄取并排泄至膀胱,肝、血、肠见摄取,脑未见摄取。
- SPECT与伽马计数器Spearman相关系数0.92,SPECT与GF-AAS为0.84,GF-AAS与伽马计数器为0.97(均P<0.0001)。
关键数值与推荐
- 模型图像质量评估:放射性棒模型棒径0.85-1.7毫米,填充1 MBq 195mPt,采集时间10-120分钟。
- 小鼠成像:四只健康小鼠静脉注射3-4 MBq 195mPt,NanoSPECT采集120分钟,时间点为注射后0、2、4或24小时。
- 定量准确性:SPECT与伽马计数器相关系数0.92,SPECT与GF-AAS为0.84,GF-AAS与伽马计数器为0.97(均P<0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In vivo biodistribution imaging of platinum-based compounds may allow better patient selection for treatment with chemo(radio)therapy. Radiolabeling with Platinum-195m (195mPt) allows SPECT imaging, without altering the chemical structure or biological activity of the compound. We have assessed the feasibility of 195mPt SPECT imaging in mice, with the aim to determine the image quality and accuracy of quantification for current preclinical imaging equipment. METHODS: Enriched (>96%) 194Pt was irradiated in the High Flux Reactor (HFR) in Petten, The Netherlands (NRG). A 0.05 M HCl 195mPt-solution with a specific activity of 33 MBq/mg was obtained. Image quality was assessed for the NanoSPECT/CT (Bioscan Inc., Washington DC, USA) and U-SPECT+/CT (MILabs BV, Utrecht, the Netherlands) scanners. A radioactivity-filled rod phantom (rod diameter 0.85-1.7 mm) filled with 1 MBq 195mPt was scanned with different acquisition durations (10-120 min). Four healthy mice were injected intravenously with 3-4 MBq 195mPt. Mouse images were acquired with the NanoSPECT for 120 min at 0, 2, 4, or 24 h after injection. Organs were delineated to quantify 195mPt concentrations. Immediately after scanning, the mice were sacrificed, and the platinum concentration was determined in organs using a gamma counter and graphite furnace - atomic absorption spectroscopy (GF-AAS) as reference standards. RESULTS: A 30-min acquisition of the phantom provided visually adequate image quality for both scanners. The smallest visible rods were 0.95 mm in diameter on the NanoSPECT and 0.85 mm in diameter on the U-SPECT+. The image quality in mice was visually adequate. Uptake was seen in the kidneys with excretion to the bladder, and in the liver, blood, and intestine. No uptake was seen in the brain. The Spearman correlation between SPECT and gamma counter was 0.92, between SPECT and GF-AAS it was 0.84, and between GF-AAS and gamma counter it was0.97 (all p < 0.0001). CONCLUSION: Preclinical 195mPt SPECT is feasible with acceptable tracer doses and acquisition times, and provides good image quality and accurate signal quantification.
引用
- Aalbersberg EA, de Wit-van der Veen BJ, Zwaagstra O, et al. Preclinical imaging characteristics and quantification of Platinum-195m SPECT. Eur J Nucl Med Mol Imaging. 2017. PMID: 28190123. doi:10.1007/s00259-017-3643-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。